OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Goy on the Management of Patients With Genetic Abnormalities and Low Risk in MCL

March 14th 2023

Andre H. Goy, MD, discusses the appropriate monitoring and management of patients with mantle cell lymphoma who display genetic abnormalities but are not considered to be high risk.

Dr. Harding on the Management of Immune-related AEs in Advanced Biliary Tract Cancer

March 14th 2023

James Harding, MD, discusses the management of immune-related adverse effects in patients with advanced biliary tract cancer.

Dr. Rampal on the Role of JAK Inhibitors in Myelofibrosis

March 14th 2023

Raajit K. Rampal, MD, PhD, discusses how the role of JAK inhibitors will continue to evolve in the treatment of patients with myelofibrosis.

Dr. Sauter on the Potential Role of BTK Inhibitors in Frontline CNS Lymphoma

March 14th 2023

Craig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.

Dr. Richardson on Proteasome Inhibitor/Monoclonal Antibody Combinations in Myeloma

March 14th 2023

Paul G. Richardson, MD, discusses the impact of combining proteasome inhibitors and monoclonal antibodies in multiple myeloma.

Dr. Iagaru on Advancements in PSMA-PET Imaging for Prostate Cancer

March 13th 2023

Andrei H. Iagaru, MD, discusses key points from his presentation on the use of novel vs conventional imaging to manage metastatic hormone-sensitive prostate cancer.

Dr. Hwang on First-line Treatment Options in HCC

March 13th 2023

Jimmy Hwang, MD, discusses currently available first-line treatment options in hepatocellular carcinoma, and areas of continued unmet need in this space.

Dr. Goy on Different Presentations of MCL

March 13th 2023

Andre H. Goy, MD, discusses differentiating between disease presentations in mantle cell lymphoma.

Dr. Calais on the Role of PSMA-PET Imaging in mCRPC

March 10th 2023

Jeremie Calais, MD, MSc, discusses the role of prostate-specific membrane antigen-PET imaging in metastatic-castrate resistant prostate cancer, and touches on the importance of integrating PSMA-PET imaging into community settings for clinical practice.

Dr. Dorff on the Continued Investigation of Upfront Chemotherapy in mHSPC

March 10th 2023

Tanya Dorff, MD, discusses key data supporting the use of intensified triplet regimens in metastatic hormone-sensitive prostate cancer, and remaining questions regarding the role of chemotherapy agents in these combinations.

Dr. Rettig on the Evolving Use of Triplet Regimens in mHSPC

March 10th 2023

Matthew Rettig, MD, discusses the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer, as well as the importance of considering key prognostic factors when utilizing this approach.

Dr. Johnson on the Importance of Diverse Representation in Breast Cancer Clinical Trials

March 10th 2023

Nathalie McDowell Johnson, MD, FACS, discusses the importance of diverse representation in breast cancer clinical trials.

Dr. Kaklamani on CDK4/6 Inhibition Prior to Elacestrant in ER+/HER2– Breast Cancer

March 10th 2023

Virginia Kaklamani, MD, discusses the utilization of elacestrant following treatment with CDK4/6 inhibitors in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Dr. Nair on Using Yoga to Improve Quality of Life in Patients Undergoing Breast Cancer Treatments

March 10th 2023

Nita Nair, MBBS, DNB, MCh, discusses research evaluating the role of yoga as a way to improve the quality of life of patients undergoing breast cancer treatments.

Dr. Ligon on Delivering CAR T-cell Therapy via Mediport Lines in Pediatric B-Cell Malignancies

March 10th 2023

John Ligon, MD, discusses findings from a study investigating the use of mediports to deliver CAR T-cell therapy in patients at Pediatric Real-World CAR Consortium medical centers.

Dr. Shah on Zamto-cel in R/R DLBCL

March 10th 2023

Nirav N. Shah, MD, discusses findings from a preplanned interim futility analysis of the single-arm phase 2 DALY II USA trial in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Mascarenhas on the Benefit of Fedratinib in Myelofibrosis

March 9th 2023

John Mascarenhas, MD, discusses the benefit of fedratinib for patients with myelofibrosis.

Dr. Villalona-Calero on KB-0742 in Solid Tumors and NHL

March 9th 2023

Miguel Villalona-Calero, MD, discusses the unique mechanism of action of the CDK9 inhibitor KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma.

Dr. Wainberg on the Rationale for the Phase 3 NAPOLI 3 Trial in Patients With PDAC

March 9th 2023

Zev A. Wainberg, MD, discusses the rationale behind the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Torka on BTK Inhibitors Available for Patients With R/R MCL

March 9th 2023

Pallawi Torka, MD, discusses the BTK inhibitors available for treatment of patients with relapsed/refractory mantle cell lymphoma.